| Literature DB >> 15177466 |
W N Washburn1, C-Q Sun, G Bisacchi, G Wu, P T Cheng, P M Sher, D Ryono, A V Gavai, K Poss, R N Girotra, P J McCann, A B Mikkilineni, T C Dejneka, T C Wang, Z Merchant, M Morella, C M Arbeeny, T W Harper, D A Slusarchyk, S Skwish, A D Russell, G T Allen, B Tesfamariam, B H Frohlich, B E Abboa-Offei, M Cap, T L Waldron, R J George, D Young, K E Dickinson, A A Seymour.
Abstract
A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human beta3 adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent beta3 full agonist (Ki = 93 nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clinical evaluation.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15177466 DOI： 10.1016/j.bmcl.2004.04.074
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823